TrialBMJ open2015

Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.

Sobha Sivaprasad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.